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Introduction 
Thrombocytopenia in association with 
human immunodeficiency virus (HIV) 
infection was described in the medical 
literature even before the term HIV was 
coined.
1
 The authors linked thrombo-
cytopenia to disorders of immune regulation 
in young men who had sex with men. 
Thrombocytopenia can be found at any stage 
during the course of illness with its 
prevalence ranging from 10-30% for mild 
thrombocytopenia (< 1.50 x 10
9
/L), to 1.5-
9% for severe thrombocytopenia (< 50 x 
10
9
/L).
2,3
 
The mechanism producing thrombo-
cytopenia in HIV infection is multifactorial 
with evidence implicating both the direct 
and indirect role played by HIV in 
decreasing platelet turnover and immune-
mediated peripheral destruction of platelets. 
How HIV alters the internal milieu of the 
bone marrow resulting in ineffective 
thrombopoiesis is still a mystery. In-vitro 
studies of megakaryocytes show quantitative 
and qualitative abnormalities in patients 
with HIV infection,
4,5
 while the peripheral 
destruction has been attributed to molecular 
mimicry of immunodominant epitopes of 
these mutating strains.
6
 
The past decade has transformed our 
understanding of HIV and acquired immune 
deficiency syndrome (AIDS) and offered a 
better perspective into its natural history. 
With the introduction of aggressive combi-
nation antiretroviral therapy (cART or 
highly active antiretroviral therapy, 
HAART) and continued research towards 
better therapeutic options, survival in 
individuals with this once dreaded infection 
has increased considerably. We report a case 
of HIV-associated thrombocytopenia who 
presented with severe bleeding despite being 
on cART for a considerable period of time. 
 
Case Report 
A 35-year-old female presented to the 
emergency department with complains of 
menorrhagia, bleeding from the gums, and 
bruises of three weeks duration over her 
lower extremities. She was diagnosed with 
HIV-1 infection four years prior and had 
been on cART (stavudine, lamivudine, 
nevirapine) since diagnosis. Her complete 
hemogram revealed a reduced platelet count 
of 8 x 10
9
/L. She was transfused with 
platelet concentrate and was admitted for 
further management. 
Her detailed medical history was 
unremarkable except for a viral flu-like, 
febrile illness four years prior, during which 
she was diagnosed with HIV-1. The 
possibility of horizontal transmission was 
deduced, since her husband indulged in 
high-risk behavior and was infected with the 
same strain. Physical examinations revealed 
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multiple petechial and purpuric lesions, 
varying in size between 0.2 to 0.8 cm, 
localized predominantly to the extensor 
compartment of the lower limbs bilaterally, 
extending up to the knees with a few 
discrete patches over the abdomen. She was 
asymptomatic with respect to HIV infection 
and any related opportunistic infection. 
Baseline renal and liver functions tests 
were normal. Her coagulation profile was 
unremarkable except for prolonged bleeding 
time (8 min; 32 sec). HbSAg titres and anti- 
HCV antibody titres were negative. Bone 
marrow examination revealed megakaryo-
cytic thrombocytopenia. Her absolute CD4 
count was 356/mcl and viral load was 
10,200 copies/ml. 
The patient was started on oral 
prednisolone 60 mg/day after explaining the 
potential risks, since the option of 
intravenous immunoglobulin was declined 
due to monetary constraints. Additional 
units of platelet concentrate were transfused 
until the second day post-admission and 
were abandoned when active bleeding 
stopped. Simultaneously, her cART regimen 
was revamped and she was started on 
zidovudine, lamivudine, and indinavir. Her 
platelet count improved in the following 
days with no evidence of any further 
bleeding. By the fifth day post-admission, 
the platelet count was 8 x 10
9
/L and she was 
discharged on the seventh day with a platelet 
count of greater than 10 x 10
9
/L.  
The patient was followed weekly with an 
intention to titrate the dose of prednisolone 
appropriately. By the end of week 6, she 
maintained a platelet count of greater than 
20 x 10
9
/L on 10 mg prednisolone every 
other day. Her viral load decreased to less 
than 200 copies/ml and prednisolone was 
stopped. She maintained complete remission 
throughout the course of a 6-month follow-
up period with platelet counts of greater than 
20 x 10
9
/L and HIV-RNA copies suppressed 
to less than 200/ml. 
Discussion 
The mainstay in the treatment of HIV-
associated thrombocytopenia is combination 
antiretroviral therapy (cART).
7
 Life-
threatening bleeding is treated with a short 
course of anti-RhD or intravenous 
immunoglobulin. Rapid response with 
dramatic increases in platelet counts is seen 
albeit short-lived, necessitating repeat 
administration of these agents to maintain 
platelet counts in the near normal range.
8,9
 
Corticosteroids have been tried as a cost-
effective modality, but its inability to sustain 
remission after tapering and the risk of 
opportunistic infections on continuous use 
have precluded its widespread use. 
Thrombocytopenia of less than 10 x 
10
9
/L is uncommon in HIV infection, 
especially in the setting of aggressive 
treatment with cART. Our patient, who 
received cART at the outset, had a benign 
clinical course with suppression of plasma 
viremia to undetectable levels. The striking 
feature of this acute presentation was the 
simultaneous increase in plasma viremia 
which coincided with severe reduction in 
platelet count, implying thrombocytopenia 
may be primarily a manifestation of the 
active driving force behind this disease-viral 
replication. Interrupting cART is known to 
increase the risk of thrombocytopenia.
10
 
Factors contributing to the decline in 
platelets after interrupting antiretroviral 
therapy may include activation of 
coagulation pathways or HIV-1 replication. 
However, this possibility was ruled out in 
our patient since she had regular follow-up 
and strictly adhered to her treatment 
regimen. Whether this sudden burst in 
replication is an early manifestation of drug 
resistance is debatable.  
The observed response seen after 
initiation of corticosteroid therapy confirms 
that anti-HIV antibodies played a role in 
destruction of platelets similar to the 
mechanism seen in settings of autoimmune 
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thrombocytopenic purpura.
11
 The sustained 
response manifested as elevated platelet 
counts for a prolonged period even after the 
withdrawal of steroids confirms the multi-
factorial etiology of HIV-associated throm-
bocytopenia and implies a role for active 
viral replication as the etiology of low 
platelets. 
In severe thrombocytopenia, elevated 
platelet counts are well documented in 
treatment-naïve as well as ART-experienced 
individuals after the introduction of cART. 
Studies have confirmed the efficacy of 
cART in this regard.
7,12
 For decades, 
zidovudine has been an integral component 
of cART in severe thrombocytopenia, with 
its efficacy attributed to suppression of viral 
load, thereby attenuating the infection of 
megakaryocytes. Its ability to increase 
platelet production is thought to play an 
important role.
13-15 
Plasma viremia in our patient, after the 
introduction of zidovudine and protease 
inhibitor to the cART regimen, was 
suppressed and undetectable after six weeks. 
Corticosteroids were withdrawn by the end 
of six weeks. The favorable response 
beyond six weeks is attributed to the clinical 
efficacy of modified cART. Although the 
exact mechanism of action cannot be 
elucidated, suppression of plasma viremia 
quantified by serial measurements and 
corresponding clinical outcome suggest that 
efficacy of cART in reducing the viral load 
played an important role. 
In an era where our understanding of 
HIV infection has gone beyond the 
molecular levels, thrombocytopenia 
associated with HIV remains elusive. 
Ongoing research in this field might help 
understand this condition better. Until 
concrete evidence is available, it is wise to 
implement zidovudine-based cART in 
patients with mild to moderate thrombo-
cytopenia and reserve corticosteroids for life 
threatening bleeding not responding to 
intravenous immunoglobulin therapy. 
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